Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer.
Authors
Hiew, KennethHart, Claire A
Ali, Adnan
Elliott, Tony
Ramani, Vijay A C
Sangar, Vijay K
Lau, Maurice W
Maddineni, Satish B
Brown, Michael D
Clarke, Noel W
Affiliation
Genito Urinary Cancer Research Group, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester, UKIssue Date
2018-04-23
Metadata
Show full item recordAbstract
Docetaxel chemotherapy is a standard of care for metastatic castrate-resistant prostate cancer (mCRPC): 40-50% of patients achieve a biochemical response. However, there is a lack of response predictive biomarkers.Citation
Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer. 2018, Eur Urol FocusJournal
European Urology FocusDOI
10.1016/j.euf.2018.04.006PubMed ID
29699892Type
ArticleLanguage
enISSN
2405-4569ae974a485f413a2113503eed53cd6c53
10.1016/j.euf.2018.04.006
Scopus Count
Collections
Related articles
- Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
- Authors: Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG
- Issue date: 2018 Nov 19
- Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
- Authors: Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS
- Issue date: 2018 Sep
- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
- Authors: Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J
- Issue date: 2018 Aug
- The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
- Authors: Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES
- Issue date: 2014 Oct
- Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
- Authors: Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN
- Issue date: 2015 Jan